We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Reversal of Alzheimer's Symptoms Achieved Within Minutes

By HospiMedica staff writers
Posted on 30 Jan 2008
A new study has shown marked improvement in a patient with Alzheimer's disease within minutes of administration of an anti tumor necrosis factor (TNF) therapeutic, a critical component of the brain's immune system.

Researchers at the University of California, Los Angeles (UCLA, USA) hypothesized that elevated levels of TNF-alpha in Alzheimer's disease interfere with the normal regulation of the transmission of neural impulses in the brain. More...
To reduce this elevated TNF, the authors gave a patient with late-onset Alzheimer's disease an injection of an anti-TNF therapeutic called etanercept. The researchers found rapid cognitive improvement, beginning within minutes. While the study only discusses one patient, many other patients with mild to severe Alzheimer's have received the treatment and all have shown sustained and marked improvement. The study was published ahead of print on January 9, 2008, in the online edition of the Journal of Neuroinflammation.

"Rapid cognitive improvement following perispinal etanercept may be related to amelioration of the effects of excess TNF-alpha on synaptic mechanisms in Alzheimer's disease and provides a promising area for additional investigation and therapeutic intervention,” concluded lead author Edward Tobinick M.D., an assistant clinical professor of medicine at UCLA.
.
The study is accompanied by a commentary by Sue Griffin, Ph.D., of the University of Arkansas for Medical Sciences (UAMS, Little Rock, USA), who is also co-editor-in-chief of the Journal of Neuroinflammation.

"It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention,” said Dr. Griffin. "This gives all of us in Alzheimer's research a tremendous new clue about new avenues of research, which is so exciting and so needed in the field of Alzheimer's. Even though this report predominantly discusses a single patient, it is of significant scientific interest because of the potential insight it may give into the processes involved in the brain dysfunction of Alzheimer's.”

TNF-alpha has recently been recognized to be a gliotransmitter that regulates synaptic function in neural networks and also mediates the disruption in synaptic memory mechanisms, which is caused by beta-amyloid and beta-amyloid oligomers.


Related Links:
University of California, Los Angeles

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.